Avadel Pharmaceuticals Announces Publication In Clinical Therapeutics Of Data Highlighting Weight Loss In People With Narcolepsy Treated With LUMRYZ Extended-Release Oral Suspension

Author: Benzinga Newsdesk | August 20, 2024 08:02am

Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the publication of results of a post-hoc analysis from the completed pivotal Phase 3 REST-ON clinical trial demonstrating greater weight loss in patients who received LUMRYZ compared with placebo. The paper, titled "Weight Loss With Once-nightly Sodium Oxybate for the Treatment of Narcolepsy: Analysis From the Phase III Randomized study Evaluating the efficacy and SafeTy of a ONce nightly formulation of sodium oxybate (REST-ON) Trial," was published online in Clinical Therapeutics.

Posted In: AVDL